Stay tuned
Takeda pledges close to $765M for plasma-derived therapy production site in Japan
Takeda pledges close to $765M for plasma-derived therapy production s
England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for ultra-rare disease
England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for
Nonprofit taps Catalent to help make dream of over-the-counter naloxone a reality
Nonprofit taps Catalent to help make dream of over-the-counter naloxo
Cidara gains first FDA approval, $20M milestone payment as FDA endorses Rezzayo
Cidara gains first FDA approval, $20M milestone payment as FDA endors
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD sh
Stay tuned
© 1994 - 2023 B.M. Pharmaceuticals